Clinical Pharmacology

Publications

Appiah-Kubi, A; Jacob, SA; Heeney, MM; Brown, C; Creary, SE; Hollenkamp, CR; Meier, ER; Niss, O; Piccone, CM; Quarmyne, M; et al. Individualized, PK-Guided Dosing of Hydroxyurea Is Not Associated with Increased Hematologic Toxicity Compared to Weight-Based Initial Dosing: Interim Results from the Hops Trial. Blood. 2022; 140:5416-5417.

Chandra, S; Mizuno, K; Zhao, J; Davies, SM; Marsh, RA; Fukuda, T; Setchell, KD R; Vinks, AA; Mehta, PA. Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. British Journal of Clinical Pharmacology. 2022; 88:115-127.

Colman, R; Mizuno, T; Hyams, J; Noe, J; Boyle, B; Denson, L; Vinks, A; Minar, P. REAL-WORLD VEDOLIZUMAB PHARMACOKINETIC STUDY IN CHILDREN IDENTIFIES TWO NOVEL BIOMARKERS OF DRUG CLEARANCE. Inflammatory Bowel Diseases. 2022; 28:s100.

Colman, R; Mizuno, T; Hyams, J; Noe, J; Boyle, B; Denson, L; Vinks, A; Minar, P. REAL-WORLD VEDOLIZUMAB PHARMACOKINETIC STUDY IN CHILDREN IDENTIFIES TWO NOVEL BIOMARKERS OF DRUG CLEARANCE. Gastroenterology. 2022; 162:s100.

Colman, RJ; Xiong, Y; Mizuno, T; Hyams, JS; Noe, JD; Boyle, B; D’Haens, GR; van Limbergen, J; Chun, K; Yang, J; et al. Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease. Alimentary Pharmacology and Therapeutics. 2022; 55:593-603.

Dong, M; Emoto, C; Fukuda, T; Arnold, DE; Mehta, PA; Marsh, RA; Vinks, AA. Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation. British Journal of Clinical Pharmacology. 2022; 88:248-259.

Dong, M; Good, A; Vinks, AA; Ware, RE; McGann, PT. Hydroxyurea Pharmacokinetics in Young Children with Sickle Cell Anemia: Results from the Therapeutic Response Evaluation and Adherence Trial (TREAT). Blood. 2022; 140:8168-8169.

Dong, M; Sadaf, A; Vinks, AA; Ware, RE; Quinn, CT. Evaluation of Dosage and Food Effect on L-Glutamine Exposure for Sickle Cell Anemia: A Population Pharmacokinetic Analysis. Blood. 2022; 140:8256-8257.

Girdwood, ST; Dong, M; Tang, P; Stoneman, E; Jones, R; Yunger, T; Ostermeier, A; Curry, C; Forton, M; Hail, T; et al. Population Pharmacokinetic Modeling of Total and Free Ceftriaxone in Critically Ill Children and Young Adults and Monte Carlo Simulations Support Twice Daily Dosing for Target Attainment. Antimicrobial Agents and Chemotherapy. 2022; 66:e0142721.

Hirabatake, M; Mizuno, T; Kato, H; Hashida, T. Everolimus pharmacokinetics and exposure-response relationship in Japanese patients with advanced breast cancer. Frontiers in Pharmacology. 2022; 13:984002.

Minar, P; Samuels, A; Mizuno, T; Menke, F; Vogt, A; Punt, N; Vinks, A. BIOLOGIC PRECISION DOSING IS NOW AVAILABLE AT THE BEDSIDE FOR CHILDREN AND ADULTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING INFLIXIMAB. Gastroenterology. 2022; 162:s98-s99.

Minar, P; Samuels, A; Mizuno, T; Menke, F; Vogt, A; Punt, N; Vinks, A. BIOLOGIC PRECISION DOSING IS NOW AVAILABLE AT THE BEDSIDE FOR CHILDREN AND ADULTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING INFLIXIMAB. Inflammatory Bowel Diseases. 2022; 28:s98-s99.

Mizuno, K; Dandoy, CE; Teusink-Cross, A; Davies, SM; Vinks, A; Jodele, S. 187 Eculizumab Precision Dosing Algorithm for TA-TMA in Children and Young Adults Undergoing Stem Cell Transplant. Transplantation and cellular therapy. 2022; 28:s154-s155.

Mizuno, K; Dandoy, CE; Teusink-Cross, A; Davies, SM; Vinks, AA; Jodele, S. Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Blood Advances. 2022; 6:1454-1463.

Mizuno, T; Dong, M; Taylor, ZL; Ramsey, LB; Vinks, AA. Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient care. British Journal of Clinical Pharmacology. 2022; 88:1418-1426.

Samuels, A; Punt, N; Reifenberg, J; Mizuno, T; Colman, R; Menke, F; Vogt, A; Vinks, A; Minar, P. PREDICTIVE PERFORMANCE OF DIFFERENT POPULATION PHARMACOKINETIC MODELS IN A REAL-WORLD COHORT OF CROHN’S DISEASE PATIENTS. Inflammatory Bowel Diseases. 2022; 28:s99-s100.

Samuels, A; Punt, N; Reifenberg, J; Mizuno, T; Colman, R; Menke, F; Vogt, A; Vinks, A; Minar, P. PREDICTIVE PERFORMANCE OF DIFFERENT POPULATION PHARMACOKINETIC MODELS IN A REAL-WORLD COHORT OF CROHN’S DISEASE PATIENTS. Gastroenterology. 2022; 162:s99-s100.

Tang Girdwood, S; Pavia, K; Paice, K; Hambrick, HR; Kaplan, J; Vinks, AA. β-lactam precision dosing in critically ill children: Current state and knowledge gaps. Frontiers in Pharmacology. 2022; 13:1044683.

van Hoogdalem, MW; Johnson, TN; McPhail, BT; Kamatkar, S; Wexelblatt, SL; Ward, LP; Christians, U; Akinbi, HT; Vinks, AA; Mizuno, T. Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome. Clinical Pharmacology and Therapeutics. 2022; 111:496-508.

van Hoogdalem, MW; Wexelblatt, SL; Akinbi, HT; Vinks, AA; Mizuno, T. A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome. Pharmacology and Therapeutics. 2022; 234:108045.

Yi, JS; Perla, S; Huang, Y; Mizuno, K; Giordano, FJ; Vinks, AA; Bennett, AM. Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines. Cardiovascular Drugs and Therapy. 2022; 36:589-604.